US20140142318A1 - Pyridylacetylenes for use as radiotracers and imaging agents - Google Patents

Pyridylacetylenes for use as radiotracers and imaging agents Download PDF

Info

Publication number
US20140142318A1
US20140142318A1 US14/162,885 US201414162885A US2014142318A1 US 20140142318 A1 US20140142318 A1 US 20140142318A1 US 201414162885 A US201414162885 A US 201414162885A US 2014142318 A1 US2014142318 A1 US 2014142318A1
Authority
US
United States
Prior art keywords
compound
methyl
cyclohex
enone
ylethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/162,885
Inventor
Fabrizio Gasparini
Yves Auberson
Lea Kessler
Simon Mensah Ametamey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to US14/162,885 priority Critical patent/US20140142318A1/en
Publication of US20140142318A1 publication Critical patent/US20140142318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.
  • R is CH 3 , (CH 2 ) n I, (CH 2 ) n Br or (CH 2 ) n F, n being 1, 2, 3 or 4 in free base or acid addition salt form.
  • R is 11 CH 3 , ( 3 H) 3 C, (CH 2 ) n 123 I, (CH 2 ) n 76 Br or (CH 2 ) n 18 F, n being 1,2, 3 or 4 in free base or acid addition salt form.
  • the compounds can exist as pure stereoisomers or mixtures thereof.
  • the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of
  • R a is respectively 11 CH 3 or ( 3 H) 3 C, reacting the compound of formula II
  • the reactions can be effected according to known methods, for example as described in the Examples.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter “markers”, for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu5 receptor).
  • agents of the invention are useful as markers for labeling the central and peripheral mGlu5 receptors in vitro or in vivo (see Example 5-7).
  • the agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGlu5 receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.
  • the present invention provides an agent of the invention for use as a marker for neuroimaging.
  • the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vivo and in vitro comprising an agent of the invention.
  • the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
  • the method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure.
  • Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • Product purification is accomplished by reversed phase HPLC using a C-18 ⁇ -Bondapak column (7.8 ⁇ 300 mm) and a mobile phase consisting of CH 3 CN/0.1% H 3 PO 4 (70/30) at a flow rate of 5 ml/min.
  • the retention time of the desired product is between 6 and 7 min.
  • the starting materials are prepared as described hereafter:
  • the title compound can be prepared by reacting 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime with [ 3 H]-Mel (0.5 equivalent) in the presence of K 2 CO 3 in DMF at 100° C. for 180 min, followed by a purification by reversed phase chromatography.
  • the reaction mixture is purified through a tC-18 Sep-Pak cartridge, and the fractions containing the desired product are further purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300 ⁇ 7.8 mm) and a mobile phase consisting of CH 3 CN/0.01 M H 3 PO 4 (70/30) at a flow rate of 4 ml/min.
  • the fraction containing the product (retention time between 12 and 13 min) is passed through a tC-18 Sep-Pak cartridge and eluted with 1 ml of ethanol. This ethanolic solution is buffered with 0.15M phosphate buffer to give after sterile filtration an isotonic and injectable solution.
  • Each animal received 250-300 pmol (0.6-40 MBq) of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[ 11 C-methyl]-oxime via a lateral tail vein.
  • the animals are sacrificed 30 min post-injection. Organ or brain regions such as hippocampus, striatum, cortex and cerebellum are removed and measured in a gamma-counter. The tissue distribution is expressed as percentage of injected dose per gram wet tissue (% ID/g organ).
  • K1, K2, K3 are individual values for control animals.
  • B1, B2, B3 are individual values for animals co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.

Description

  • The present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.
  • More particularly the invention provides a compound of formula I
  • Figure US20140142318A1-20140522-C00001
  • wherein
  • R is CH3, (CH2)nI, (CH2)nBr or (CH2)nF, n being 1, 2, 3 or 4 in free base or acid addition salt form.
  • Compounds of the formula I are preferred, wherein
  • R is 11CH3, (3H)3C, (CH2)n 123I, (CH2)n 76Br or (CH2)n 18F, n being 1,2, 3 or 4 in free base or acid addition salt form.
  • In the case of possible stereoisomerism, e.g. cis/trans-isomerism of double bonds, the compounds can exist as pure stereoisomers or mixtures thereof.
  • In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of
      • a) for the production of a compound of formula Ia
  • Figure US20140142318A1-20140522-C00002
  • wherein Ra is respectively 11CH3 or (3H)3C, reacting the compound of formula II
  • Figure US20140142318A1-20140522-C00003
      • with respectively 11CH3I or C(3H)3I, in the presence of a base, or
      • b) for the production of a compound of formula Ib
  • Figure US20140142318A1-20140522-C00004
      • wherein Rb is respectively (CH2)n 18F, (CH2)n 123I or (CH2)n 76Br, reacting a compound of formula III
  • Figure US20140142318A1-20140522-C00005
      • wherein n is as defined above and X is OTs or OMs, with respectively 18F⊖, 123I⊖ or 76Br⊖, or reacting the compound of formula II with a compound of formula IV

  • X—Rb   IV
      • wherein X and Rb are as defined above,
  • and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.
  • The reactions can be effected according to known methods, for example as described in the Examples.
  • Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • The starting materials of formulae II, III and IV are known or may be obtained in analogous manner to know procedures, e.g. as described in the Examples.
  • Compounds of formula I in free base or acid addition salt form, hereinafter referred to as agents of the invention, exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter “markers”, for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu5 receptor).
  • More particularly the agents of the invention are useful as markers for labeling the central and peripheral mGlu5 receptors in vitro or in vivo (see Example 5-7).
  • The agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGlu5 receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.
  • In accordance with the above, the present invention provides an agent of the invention for use as a marker for neuroimaging.
  • In a further aspect, the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vivo and in vitro comprising an agent of the invention.
  • In still a further aspect, the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
  • The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure. Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.
  • The following examples illustrate the invention.
    • EXAMPLE 1 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[11C-methyl]-oxime
  • 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O[11C-methyl]-oxime is synthesized by reacting [11C]-Mel with the sodium salt of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (1 mg) in dry DMF (400 μl). [11C]-Mel is introduced via a slow stream of helium and when addition is completed the reaction mixture is heated to 120° C. for 10 min. Product purification is accomplished by reversed phase HPLC using a C-18 μ-Bondapak column (7.8×300 mm) and a mobile phase consisting of CH3CN/0.1% H3PO4 (70/30) at a flow rate of 5 ml/min. The retention time of the desired product is between 6 and 7 min.
  • 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O[11C-methyl]-oxime is formulated in a solution containing polysorbatum (2%), ethanol (10%) and saline (0.9%).
  • LogD=2.5 (determined using the classical shake-flask method).
  • The starting materials are prepared as described hereafter:
      • a) 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone
  • A solution of 2-ethynyl-6-methyl-pyridine (702 mg, 6 mmol), 3-bromo-cyclohex-2-enone (1.26 g, 7.2 mmol), bis-(triphenylphosphine)-palladium-dichloride (168 mg, 0.24 mmol), copper(I) iodide (93 mg, 0.48 mmol), triethylamine (4.8 ml, 34.4 mmol) in 12ml DMF is heated to 55° C. for 1 h. After that time the solution is diluted with ethyl acetate (500 ml) and washed with sat aq. NaHCO3 (1×150 ml). The water phase is extracted with ethyl acetate (1×150 ml) and the combined organic phases are dried over Na2SO4, filtered and concentrated in vacuo. The residue (1.88 g) is purified on column chromatography (silica gel, eluent hexane/ethyl acetate 3:1 v/v) and the fractions containing the desired compound are collected and concentrated in vacuo to yield 1.05 g (yield=82%) of the title compound as a light yellow oil.
      • b) 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime
  • A solution of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone (422 mg, 2 mmol) and hydroxylamine hydrochloride (278 mg, 4 mmol) in pyridine (20 ml) is stirred for 17 h at RT. After that time the solvent is evaporated in vacuo. The residue is dissolved in ethyl acetate (300 ml) and washed with sat NaHCO3 (1×50 ml). The water phase is extracted with ethyl acetate (1×50 ml). The combined organic phases are dried over Na2SO4, filtered and concentrated in vacuo. The residue (0.45 g) is purified on column chromatography (Silica gel, eluent hexane/ethyl acetate 2:1 v/v) and the fractions containing the desired compound are collected and concentrated in vacuo to yield 0.192 g (yield=42%) of the title compound as light yellow crystals, m.p. 166-168° C.
    • EXAMPLE 2 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[tri(3H)-methyl]-oxime
  • The title compound can be prepared by reacting 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime with [3H]-Mel (0.5 equivalent) in the presence of K2CO3 in DMF at 100° C. for 180 min, followed by a purification by reversed phase chromatography.
    • EXAMPLE 3 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-(2-[18F-fluoro]-ethyl)-oxime
  • The sodium salt of the 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (2 mg) is reacted in dry DMF (400 μl) with [18F]-2-fluoro-ethyltosylate (obtained from ethyleneditosylate and [18F]-KF-Kryptofix complex) at 100° C. for 10 min. The reaction mixture is purified through a tC-18 Sep-Pak cartridge, and the fractions containing the desired product are further purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300×7.8 mm) and a mobile phase consisting of CH3CN/0.01 M H3PO4 (70/30) at a flow rate of 4 ml/min. The fraction containing the product (retention time between 12 and 13 min) is passed through a tC-18 Sep-Pak cartridge and eluted with 1 ml of ethanol. This ethanolic solution is buffered with 0.15M phosphate buffer to give after sterile filtration an isotonic and injectable solution.
    • EXAMPLE 4 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[18F-fluoro]-methyl)-oxime
  • The sodium salt of the 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (2 mg) is reacted in dry DMF (400 μl) with [18F]CH2OTf at 100° C. for 30 min. After an initial purification by passing the reaction mixture through a tC-18 Sep-Pak cartridge, 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[18F-fluoro]-methyl-oxime was finally purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300×7.8 mm) and a mobile phase consisting of CH3CN/0.01M H3PO4 (70/30) at a flow rate of 4 ml/min. The product is formulated in analogy to 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-(2-[18F-fluoro]-ethyl)-oxime (example 3).
    • EXAMPLE 5 Ki/IC50 Determination (Binding Assay)
  • In vitro, the affinity for the mGlu5 receptor is determined using a radioligand displacement technique as described by Gasparini et al, Biorg. Med. Chem. Lett. 2002, 12, 407-409. 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-methyl-oxime shows an IC50 of 8 nM (Hill coefficient 1.08; 95% confidence intervals: 6.0-10.0 nM) for the displacement of [3H]-2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine from membrane of L-tk cells stably expressing the human mGlu5 receptor (Daggett et al, Neuropharm. 1995, 34:871-886). Using the Cheng-Prusoff equation, a Ki of 4 nM is calculated (radioligand concentration used for the assay: 2 nM).
    • EXAMPLE 6 Organ and Brain Structure Distribution
  • Two groups of male adult Sprague-Dawley rats weighing 250-300 g are used for the biodistribution studies. The first group (n=3) serves as the control group and the second group (n=3) serves as the blockade group. Each animal received 250-300 pmol (0.6-40 MBq) of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[11C-methyl]-oxime via a lateral tail vein. The blockade group is co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine (1 mg/kg) whereas the control group (n=3) receives a corresponding volume of 0.9% NaCl. The animals are sacrificed 30 min post-injection. Organ or brain regions such as hippocampus, striatum, cortex and cerebellum are removed and measured in a gamma-counter. The tissue distribution is expressed as percentage of injected dose per gram wet tissue (% ID/g organ).
    • EXAMPLE 7 Results of the Brain Distribution Study with 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[11C-methyl]-oxime
  • The table below displays the percentage of the injected dose normalized per gram of tissue. K1, K2, K3 are individual values for control animals. B1, B2, B3 are individual values for animals co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine.
  • Organ K1 K2 K3 B1 B2 B3
    Hippocampus 0.16154 0.25440 0.21264 0.05184 0.06195 0.05972
    Striatum 0.22564 0.30685 0.28164 0.06495 0.07158 0.06487
    Cortex 0.14849 0.18316 0.16909 0.04964 0.05582 0.05431
    Cerebellum 0.03322 0.03925 0.03699 0.04052 0.03608 0.03421
    Midbrain 0.07703 0.10559 0.09091 0.03876 0.04700 0.04422
    Restbrain 0.05519 0.06520 0.06070 0.03832 0.04762 0.04383
    Whole brain 0.11123 0.13659 0.12999 0.04580 0.05118 0.04951

Claims (15)

1. A compound having a structure that is embraced within the genus of formula I
Figure US20140142318A1-20140522-C00006
wherein R is 11CH3, (3H)3C, (CH2)n123I, (CH2)n76Br or (CH2)n18F, n being 1,2, 3 or 4;
in free base or acid addition salt form, and which exhibits activity as an mGluR5 receptor antagonist.
2. The compound of claim 1, wherein R is 11CH3.
3. The compound of claim 1, wherein R is (3H)3C.
4. The compound of claim 1, wherein R is (CH2)123I.
5. The compound of claim 1, wherein R is (CH2)2123I.
6. The compound of claim 1, wherein R is (CH2)3123I.
7. The compound of claim 1, wherein R is (CH2)4123I.
8. The compound of claim 1, wherein R is (CH2)76Br.
9. The compound of claim 1, wherein R is (CH2)276Br.
10. The compound of claim 1, wherein R is (CH2)376Br.
11. The compound of claim 1, wherein R is (CH2)476Br.
12. The compound of claim 1, wherein R is (CH2)18F.
13. The compound of claim 1, wherein R is (CH2)218F.
14. The compound of claim 1, wherein R is (CH2)318F.
15. The compound of claim 1, wherein R is (CH2)418F.
US14/162,885 2003-09-26 2014-01-24 Pyridylacetylenes for use as radiotracers and imaging agents Abandoned US20140142318A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/162,885 US20140142318A1 (en) 2003-09-26 2014-01-24 Pyridylacetylenes for use as radiotracers and imaging agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0322612.3A GB0322612D0 (en) 2003-09-26 2003-09-26 Organic compounds
GB0322612.3 2003-09-26
PCT/EP2004/010743 WO2005030723A1 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents
US10/573,162 US8674110B2 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents
US14/162,885 US20140142318A1 (en) 2003-09-26 2014-01-24 Pyridylacetylenes for use as radiotracers and imaging agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/573,162 Continuation US8674110B2 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents
PCT/EP2004/010743 Continuation WO2005030723A1 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents

Publications (1)

Publication Number Publication Date
US20140142318A1 true US20140142318A1 (en) 2014-05-22

Family

ID=29286926

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/573,162 Expired - Fee Related US8674110B2 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents
US14/162,885 Abandoned US20140142318A1 (en) 2003-09-26 2014-01-24 Pyridylacetylenes for use as radiotracers and imaging agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/573,162 Expired - Fee Related US8674110B2 (en) 2003-09-26 2004-09-24 Pyridylacetylenes for use as radiotracers and imaging agents

Country Status (13)

Country Link
US (2) US8674110B2 (en)
EP (1) EP1670762B1 (en)
JP (1) JP4965255B2 (en)
CN (1) CN100430380C (en)
AU (2) AU2004275971B2 (en)
BR (1) BRPI0414732A (en)
CA (1) CA2539469C (en)
ES (1) ES2400713T3 (en)
GB (1) GB0322612D0 (en)
MX (1) MXPA06003424A (en)
PL (1) PL1670762T3 (en)
PT (1) PT1670762E (en)
WO (1) WO2005030723A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2013518085A (en) 2010-02-01 2013-05-20 ノバルティス アーゲー Pyrazolo [5,1b] oxazole derivatives as CRF-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (en) 2010-02-02 2015-01-30 Novartis Ag Cyclohexylamide derivatives as CRF receptor antagonists
WO2012004400A1 (en) * 2010-07-09 2012-01-12 Recordati Ireland Limited Novel spiroheterocyclic compounds as mglu5 antagonists
AR086554A1 (en) 2011-05-27 2014-01-08 Novartis Ag DERIVATIVES OF PIPERIDINE 3-ESPIROCICLICA AS AGRONISTS OF GHRELINE RECEPTORS
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6843979B2 (en) 1999-04-26 2005-01-18 Emory University 4-haloethenylphenyl tropane:serotonin transporter imaging agents
AU767726B2 (en) 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
WO2001001621A2 (en) * 1999-06-30 2001-01-04 Sun Microsystems, Inc. Customizing web content based on network conditions
JP4815083B2 (en) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション Heterocyclic compounds and methods of use thereof
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
JP4070431B2 (en) 2001-07-10 2008-04-02 ジーイー・ヘルスケア・リミテッド Iodine-added neuroprobe for mapping monoamine reuptake sites
US20070060618A1 (en) * 2002-10-24 2007-03-15 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding

Also Published As

Publication number Publication date
CN1856468A (en) 2006-11-01
CA2539469C (en) 2012-06-19
ES2400713T3 (en) 2013-04-11
PL1670762T3 (en) 2013-05-31
PT1670762E (en) 2013-02-07
GB0322612D0 (en) 2003-10-29
EP1670762B1 (en) 2012-12-05
JP4965255B2 (en) 2012-07-04
MXPA06003424A (en) 2006-06-20
AU2008261192A1 (en) 2009-01-22
WO2005030723A1 (en) 2005-04-07
AU2004275971A1 (en) 2005-04-07
US20090010838A1 (en) 2009-01-08
BRPI0414732A (en) 2006-11-21
EP1670762A1 (en) 2006-06-21
AU2008261192B2 (en) 2011-08-04
US8674110B2 (en) 2014-03-18
CN100430380C (en) 2008-11-05
JP2007506698A (en) 2007-03-22
AU2004275971B2 (en) 2008-10-02
CA2539469A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
US20140142318A1 (en) Pyridylacetylenes for use as radiotracers and imaging agents
JP3228422B2 (en) Iodine-loaded neuroprobe for mapping monoamine reuptake sites
TWI600650B (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN101522624B (en) Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
US5744121A (en) Serotonin (5-HT1A) receptor ligands and imaging agents
Hintermann et al. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies
JP2014519489A (en) Radiolabeled amino acids for diagnostic imaging
CN104292155A (en) Radiolabelling reagents and methods
ZA200204255B (en) Novel compounds.
EP0114573B1 (en) Imidazo(1,5-a)pyridine derivatives
SU1738088A3 (en) Method for synthesis of cis-derivatives of n-(3-hydroxy-4-piperidinyl)-benzamide
WO2004007440A1 (en) Imaging compounds
US8158782B2 (en) Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof
EP0831941B1 (en) Iodinated neuroprobes for mapping monoamine reuptake sites
WO2006107106A1 (en) Ligand for vesicular acetylcholine transporter
CA2671596A1 (en) Aurone derivative-containing composition for diagnosis
US20110064662A1 (en) Kit for producing molecular probe for pet screening for drug discovery
CN113307758B (en) P2X7 receptor targeting probe precursor labeled by medical radioactive isotope
IE883136L (en) Ó(2)-adreno receptor antagonists
EP0029420A1 (en) Novel halophenyl-pyridyl-allylamine derivatives, processes and intermediates as well as pharmaceutical preparations thereof
Lakshmi et al. (R)-N-Methyl-3-(3-125I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters
Schirrmacher et al. Radiosynthesis of (±)‐(2‐((4‐(2‐[18F] fluoro‐ethoxy) phenyl) bis (4‐methoxy‐phenyl) methoxy) ethylpiperidine‐3‐carboxylic acid: a potential GAT‐3 PET ligand to study GABAergic neuro‐transmission in vivo
US20150183743A1 (en) Compound and use of compound to prepare a radiolabelled compound
KR950011410B1 (en) A process for the preparation of heterocyclic compounds
JPS6299375A (en) Benzodioxole derivative

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION